To be GMP or not to be- a radionuclide's question.

Area of Science:

• Pharmaceutical Science
• Nuclear Medicine
• Regulatory Affairs

Background:

• Radionuclides are key components of radiopharmaceuticals, requiring adherence to pharmaceutical regulations and guidelines for production.
• Current regulations impact the use of radionuclides in clinical research and development.

Purpose of the Study:

• To analyze the pharmaceutical regulatory landscape for radionuclide production in Europe.
• To discuss challenges in novel production pathways and non-Good Manufacturing Practices (GMP) production routes.

Main Methods:

• Review of the European regulatory framework for radionuclide production.
• Discussion of Good Manufacturing Practices (GMP) implications.
• Analysis of pathways for both GMP and non-GMP radionuclide production.

Main Results:

• The current regulatory environment presents challenges for novel radionuclide production pathways.
• Non-GMP production pathways are explored as potential solutions.
• Exemptions from GMP are identified as critical for specific applications.

Conclusions:

• Exemptions from GMP requirements are essential for fostering clinical innovation with radionuclides.
• A unified understanding is necessary for the safe adoption of novel radionuclides in medicine.
• Streamlining regulatory hurdles is key to enabling user-friendly access to new medical radionuclides.